Skip to main content
Fig. 3 | AAPS Open

Fig. 3

From: Utilizing cross-product prior knowledge to rapidly de-risk chemical liabilities in therapeutic antibody candidates

Fig. 3

Potential deamidation site de-risked using the cross-product methodology. NT at AHo 67 in H_CDR2 was identified as a potential risk in two candidate molecules (gray, right). Homology models of variable domains from molecules harboring the NT site of interest are shown as cartoons with the NT site shown as sticks. The cross-product analysis identified 7 molecules that had already been successfully commercialized that shared the same motif at the same site (green, left). Additional molecules for which we had readily available internal data showed no detectable modification at this site under tested stress conditions (blue, middle)

Back to article page